Loading...
Market
Which area will GSK prioritize in its 2025 strategy?
2
Resolution / Starting Odds
Oncology • 25%
Vaccines • 25%
Respiratory • 25%
Other • 25%
GSK's strategic reports and press releases
Story
GSK Acquires IDRx for $1 Billion and $150 Million Earnout to Boost IDRX-42 for Gastrointestinal Cancers
Jan 13, 2025, 07:50 AM
GSK has announced its agreement to acquire IDRx, Inc., a clinical-stage biotech company based in Plymouth, Massachusetts, for an upfront payment of $1 billion. The deal, which could reach a total of $1.15 billion including potential milestone payments of up to $150 million, aims to enhance GSK's portfolio in cancer treatments. IDRx is currently developing IDRX-42, a drug in Phase 1 trials targeting gastrointestinal stromal tumors (GIST) and other gastrointestinal cancers. GSK's Chief Scientific Officer, Tony Wood, expressed enthusiasm for the early data from IDRX-42, highlighting its ability to address clinically relevant KIT mutations, which are a significant gap in current treatment options. This acquisition aligns with GSK's strategy to address critical patient needs in the oncology space.
View original story
Similar markets
Partnership with another biotech • 25%
Other strategic move • 25%
Another acquisition in oncology • 25%
Focus on internal development • 25%
Neurological disorders • 25%
Other • 25%
Infectious diseases • 25%
Cancer • 25%
Treatment Access • 25%
Testing and Prevention • 25%
Research and Development • 25%
Public Awareness Campaigns • 25%
R&D and innovation • 25%
Market expansion • 25%
Operational efficiency • 25%
Partnerships and collaborations • 25%
Focus on other areas • 25%
Focus on cancer treatments • 25%
Focus on genetic engineering • 25%
Focus on both equally • 25%
A company with late-stage drug development • 25%
A company with a marketed drug • 25%
A company with mid-stage drug development • 25%
Sage Therapeutics • 25%
Digital media and entertainment • 25%
Cloud computing • 25%
Logistics and supply chain • 25%
E-commerce • 25%
Other • 25%
Dermatology • 25%
Rheumatology • 25%
Gastroenterology • 25%
Yes • 50%
No • 50%
Fully operational • 25%
Other • 25%
Not operational • 25%
Partially operational • 25%
Other • 25%
European Union • 25%
Japan • 25%
Canada • 25%